

World Journal of *Methodology*

World J Methodol 2013 September 26; 3(3): 27-38





World Journal of Methodology

A peer-reviewed, online, open-access journal of methodology

Editorial Board

2011-2015

The *World Journal of Methodology* Editorial Board consists of 323 members, representing a team of worldwide experts in methodology. They are from 45 countries, including Argentina (4), Australia (11), Austria (3), Belgium (3), Bosnia and Herzegovina (1), Brazil (4), Canada (12), China (39), Croatia (1), Cuba (1), Czech Republic (4), Denmark (2), Egypt (1), France (8), Germany (5), Greece (6), Hungary (3), India (9), Iran (3), Israel (1), Italy (25), Japan (14), Lithuania (1), Malaysia (1), Mexico (4), Netherlands (3), New Zealand (1), Norway (2), Pakistan (2), Poland (2), Portugal (3), Romania (5), Russia (2), Senegal (1), Singapore (1), South Africa (1), South Korea (4), Spain (18), Sweden (2), Thailand (3), Turkey (4), United Arab Emirates (1), United Kingdom (14), United States (87), and Uruguay (1).

EDITOR-IN-CHIEF

Yicheng Ni, *Leuven*

STRATEGY ASSOCIATE

EDITORS-IN-CHIEF

António Vaz Carneiro, *Lisboa*
Guido Gainotti, *Rome*
Val J GebSKI, *Sydney*
Bo Hang, *Berkeley*
George A Kelley, *Morgantown*
Sang-Soo Lee, *Chuncheon*
Gerhard Litscher, *Graz*
Laurentiu M Popescu, *Bucharest*

GUEST EDITORIAL BOARD MEMBERS

Wen-Hsiung Chan, *Chung Li*
Long-Sen Chang, *Kaohsiung*
Yuh-Shan Ho, *Wufeng*
Shih-Chang Lin, *Taipei*
Hung-Jen Liu, *Taichung*
Ko-Huang Lue, *Taichung*
Rong-Jong Wai, *Chung Li*
Chin-Tsan Wang, *I Lan*
Yau-Huei Wei, *Taipei*
Ching-Feng Weng, *Hualien*

MEMBERS OF THE EDITORIAL BOARD



Argentina

Paula Abate, *Córdoba*
José Miguel Belizán, *Buenos Aires*
Enrique Roberto Soriano, *Buenos Aires*
Rodolfo G Wuilloud, *Mendoza*



Australia

Felix Acker, *Melbourne*
Seetal Dodd, *Geelong*
Guy D Eslick, *Sydney*
Adrian J Gibbs, *Canberra*
Phillipa Jane Hay, *Sydney*
Moyez Jiwa, *Bentley*
Sanjay Patole, *Perth*
Clive Julian Christie Phillips, *Gatton*
Shuhong Wang, *Adelaide*
Jiake Xu, *Perth*



Austria

Gerwin A Bernhardt, *Graz*
Martin Voracek, *Vienna*



Belgium

Zeger Debyser, *Leuven*
Piet K Vanhoenacker, *Aalst*



Bosnia and Herzegovina

Abdülhamit Subasi, *Sarajevo*



Brazil

Monica L Andersen, *São Paulo*
Mariana de Andrea Hacker, *Rio de Janeiro*
Delfim Soares Júnior, *Juiz de Fora*
Moacyr A Rebello, *Rio de Janeiro*



Canada

Ahmed M Abou-Setta, *Edmonton*
Amir Azarpazhooh, *Toronto*
Kenneth R Chapman, *Toronto*
Elijah Dixon, *Calgary*
Martin A Katzman, *Toronto*
Alejandro Lazo-Langner, *London*
Richard WJ Neufeld, *London*
Louis Perrault, *Montreal*
Prakesh S Shah, *Toronto*
Léon C van Kempen, *Montreal*
Yuzhuo Wang, *Vancouver*
Haishan Zeng, *Vancouver*



China

Deng-Feng Cao, *Beijing*
Gilbert Y S Chan, *Hong Kong*
George G Chen, *Hong Kong*
William CS Cho, *Hong Kong*
Raymond Chuen-Chung, *Hong Kong*
Meng-Jie Dong, *Hangzhou*
Zhi-Sheng Duan, *Beijing*
Hani El-Nezami, *Hong Kong*
Rajiv Kumar Jha, *Xi'an*
Gang Jin, *Beijing*
Huang-Xian Ju, *Nanjing*
Hui Li, *Zhejiang*
Yun-Feng Lin, *Chengdu*
Wing-Yee Lui, *Hong Kong*
Feng-Ming Luo, *Chengdu*
Jing-Yun Ma, *Beijing*
Hong-Xiang Sun, *Hangzhou*
Ji-Bo Wang, *Shenyang*
Zhi-Ming Wang, *Chengdu*

Tong-Wen Xu, *Hefei*
Shi-Ying Xuan, *Qingdao*
Xi-Lin Yang, *Hong Kong*
Bang-Ce Ye, *Shanghai*
Wen-Wu Yu, *Nanjing*
Yue-Hong Zhang, *Hangzhou*
Zhong-Ying Zhao, *Hong Kong*
Chun-Fu Zheng, *Wuhan*
Ma Zheng, *Beijing*
Jun-Jie Zhu, *Nanjing*



Croatia

Marijeta Kralj, *Zagreb*



Cuba

Mariano R Ricard, *Habana*



Czech Republic

Kamil Kuca, *Hradec Kralove*
Bozena Novotna, *Prague*
Jiri Sedy, *Prague*
Miroslav Sip, *Ceske Budejovice*



Denmark

Morten Mørup, *Lyngby*
Hans Sanderson, *Roskilde*



Egypt

Nervana S Bayoumi, *Cairo*



France

Marc Y Bardou, *Dijon*
Mohammed M Bettahar, *Nancy*
Olivier David, *Grenoble*
Guido Kroemer, *Paris*
Florian Lesage, *Sophia Antipolis*
Patrick Maison, *Creteil*
Sandrine Marquet, *Marseille*
Jean Yves Rotge, *Bordeaux*



Germany

Harald Hampel, *Frankfurt*
Frank Peinemann, *Cologne*
M Lienhard Schmitz, *Giessen*
Alfons Schnitzler, *Duesseldorf*
Frank Werner, *Magdeburg*



Greece

Konstantinos P Economopoulos, *Athens*
Georgios A Koumantakis, *Aegion*
Michael Koutsilieris, *Athens*
Demosthenes Panagiotakos, *Athens*
Issidora Papassideri, *Athens*
Falaras Polycarpus, *Pallini Attikis*



Hungary

Péter Halász, *Budapest*
András Komócsi, *Pécs*
László Vécsei, *Szeged*



India

Dipshikha Chakravorty, *Bangalore*
DK Dhawan, *Chandigarh*
R Jayakumar, *Cochin*
Abdul Viqar Khan, *Aligarh*
Geetha Manivasagam, *Vellore*
Jacob Peedicayil, *Vellore*
YS Prabhakar, *Lucknow*
Debasish Sarkar, *Orissa*
Rakesh Kumar Sinha, *Ranchi*



Iran

Mehran Javanbakht, *Tehran*
Enayat Kalantar, *Sanandaj*
Shekoufeh Nikfar, *Tehran*



Israel

Dan Frenkel, *Tel Aviv*



Italy

Giuseppe Biondi-Zoccai, *Latina*
Carlo Bonanno, *Vicenza*
Paolo Borrione, *Turin*
Filippo Cademartiri, *Monastier di Treviso*
Alberto Chiesa, *Bologna*
Annamaria Cimini, *L'Aquila*
Giovanni Di Leo, *San Donato Milanese*
Rosario Donato, *Via del Giochetto*
Alfio Ferlito, *Udine*
Giovanna Ferraioli, *Milan*
Irene Floriani, *Milan*
Landoni Giovanni, *Milano*
Stefano Girotti, *Bologna*
Paola Irato, *Padova*
Giovanni Martinotti, *Rome*
Mario Mascalchi, *Florence*
Patrizia Mecocci, *Perugia*
Germano Orrù, *Cagliari*
Maurizio Pompili, *Rome*
Carlo Riccardi, *Perugia*
Domenico Rubello, *Rovigo*
Gianfranco Spalletta, *Rome*
Gambardella Stefano, *Rome*
Mauro Valtieri, *Rome*



Japan

Kohei Akazawa, *Niigata*
Subash CB Gopinath, *Tsukuba*
Masafumi Goto, *Miyagi*
Koichi Hattori, *Tokyo*
Satoshi Hirohata, *Okayama*
Yukihiko Ikeda, *Osaka-sayama*

Masahiro Kohzuki, *Sendai*
Yoshinori Marunaka, *Kyoto*
Kenji Miura, *Tokorozawa*
Ryuichi Morishita, *Suita*
Mitsuhiko Noda, *Tokyo*
Yurai Okaji, *Tokyo*
Hirosato Seki, *Osaka*
Hisanori Umehara, *Kahoku-gun*



Lithuania

Giedrius Barauskas, *Kaunas*



Malaysia

Iis Sopyan, *Kuala Lumpur*



Mexico

Javier Camacho, *Mexico City*
Mejía Aranguré Juan Manuel, *Col Doctores*
Martha Rodríguez-Moran, *Durango*
Julio Sotelo, *Mexico City*



Netherlands

Kristien Hens, *Maastricht*
Bart J Polder, *Emmeloord*
Frank Twisk, *Limmen*



New Zealand

Valery Feigin, *Auckland*



Norway

David F Mota, *Oslo*
Tore Syversen, *Trondheim*



Pakistan

Muhammad A Noor, *Islamabad*
Yasir Waheed, *Islamabad*



Poland

Piotr Dziegiel, *Wroclaw*
Tadeusz Robak, *Lodz*



Portugal

Nuno Lunet, *Porto*
Hugo Sousa, *Porto*



Romania

Elena Moldoveanu, *Bucharest*
Monica Neagu, *Bucharest*
Florin-Dan Popescu, *Bucharest*

Eugen Rusu, *Galati*



Russia

Galina B Bolshakova, *Moscow*
Sergey V Dorozhkin, *Moscow*



Senegal

Badara Cissé, *Dakar*



Singapore

Zhang Yong, *Singapore*



South Africa

Robin Alexander Emsley, *Cape Town*



South Korea

Sang Soo Hah, *Seoul*
Chang-Yong Lee, *Kongju*
Kwan Sik Lee, *Seoul*



Spain

Salvador F Aliño, *Valencia*
Mohamed Farouk Allam, *Cordoba*
Alejandro Cifuentes, *Madrid*
Miren Lopez de Alda, *Barcelona*
Joaquin de Haro, *Madrid*
M de la Guardia, *Valencia*
Emma Garcia-Meca, *Cartagena*
Mónica H Giménez, *Zaragoza*
Josep M Guerrero, *Barcelona*
Fernando Marin, *Madrid*
José A Orosa, *A Coruña*
Jesús Osada, *Zaragoza*
Soledad Rubio, *Córdoba*
Helmut Schröder, *Barcelona*
Jesus Simal-Gandara, *Ourense*
Bahi Takkouche, *Santiago de Compostela*
Gabriela Topa, *Madrid*
Miguel A Vallejo, *Madrid*



Sweden

Stefan Karlsson, *Lund*
Jenny Selander, *Stockholm*



Thailand

Amporn Jariyapongskul, *Bangkok*
Apiwat Mutirangura, *Bangkok*

Bungorn Sripanidkulchai, *Khon Kaen*



Turkey

Mehmet Doğan, *Çağış-Balikesir*
Ferda E Percin, *Ankara*
Ahmet Yildirim, *Bornova-Izmir*
Aysegul Yildiz, *Izmir*



United Arab Emirates

Hassib Narchi, *Al Ain*



United Kingdom

Richard H Barton, *London*
Paul Evans, *London*
Giuseppe Garcea, *Leicester*
Marta I Garrido, *London*
Sinead Keeney, *Belfast*
Maurice J O'Kane, *Londonderry*
Abdullah Pandor, *Sheffield*
Susan Pang, *Teddington*
Pankaj Sharma, *London*
Andrew Harvey Sims, *Edinburgh*
David E Whitworth, *Aberystwyth*
Sorrel E Wolowacz, *Manchester*
Feng Wu, *Headington*
Shangming Zhou, *Swansea*



United States

Nasar U Ahmed, *Miami*
Mike Allen, *Milwaukee*
Srinivas Ayyadevara, *Little Rock*
Charles F Babbs, *West Lafayette*
Janet Barletta, *Baltimore*
Lawrence T Bish, *Philadelphia*
Richard W Bohannon, *Storrs*
Mark Bounthavong, *San Diego*
M Ahmad Chaudhry, *Burlington*
Pei Chen, *Beltsville*
Tao Chen, *Jefferson*
Yong Q Chen, *Winston-Salem*
Machado Christian, *Southfield*
Patricia Ann D'Amore, *Boston*
Undurti N Das, *Shaker Heights*
Feng Ding, *Chapel Hill*
Mary E Edgerton, *Houston*
D Mark Estes, *Athens*
Bingliang Fang, *Houston*
Ronnie Fass, *Tucson*
Vesna D Garovic, *Rochester*
Alexandros Georgakilas, *Greenville*
Ronald Gillam, *Logan*
Shannon S Glaser, *Tempe*
Ga Nagana Gowda, *West Lafayette*
Anton B Guliaev, *San Francisco*
Zong Sheng Guo, *Pittsburgh*

James P Hardwick, *Rootstown*
Diane M Harper, *Kansas*
Odette A Harris, *Stanford*
Rod Havriluk, *Tallahassee*
Moonseong Heo, *Bronx*
Guoyuan Huang, *Evansville*
Michael Huncharek, *Columbia*
Reinhold J Hutz, *Milwaukee*
Bankole A Johnson, *Charlottesville*
Joseph M Kaminski, *Silver Spring*
Yong S Kim, *Bethesda*
Mark S Kindy, *Charleston*
Jennifer Kisamore, *Tulsa*
Georgios D Kitsios, *Boston*
Ronald Klein, *Shreveport*
Heidemarie Kremer, *Miami*
S Lakshmiarahan, *Norman*
Dawei Li, *New Haven*
Kenneth Maiese, *Newark*
Sameer Malhotra, *New York*
JL Mehta, *Little Rock*
Ray M Merrill, *Provo*
M Mimeault, *Nebraska*
Ron B Mitchell, *St Louis*
Anirban P Mitra, *Los Angeles*
Walter P Murphy, *Evanston*
Marja Tuuli Nevalainen, *Philadelphia*
Yan Peng, *Dallas*
George Perry, *San Antonio*
Ilona Petrikovics, *Huntsville*
Shengping Qin, *Davis*
Peter J Quesenberry, *Providence*
P Hemachandra Reddy, *Beaverton*
James V Rogers, *Columbus*
Troy Rohn, *Boise*
Paul R Sanberg, *Tampa*
Tor C Savidge, *Galveston*
Dong-Chul Seo, *Bloomington*
Igor Sevostianov, *Las Cruces*
Judy Y Tan, *Hillside*
Weihong Tan, *Gainesville*
Guangwen Tang, *Boston*
Paul D Terry, *Knoxville*
Guochuan Emil Tsai, *Torrance*
Catherine E Ulbricht, *Somerville*
Thomas TH Wan, *Orlando*
Xiao-Jing Wang, *Aurora*
Jang-Yen Wu, *Boca Raton*
Qing Wu, *Scottsdale*
Eleftherios S Xenos, *Lexington*
Lijun Xia, *Oklahoma City*
Xiong Xu, *New Orleans*
Li-Jun Yang, *Gainesville*
Wancai Yang, *Chicago*
Xinan Yang, *Chicago*
Fahd A Zarrouf, *Anderson*
Henry Zeringue, *Pittsburgh*
Jingbo Zhang, *New York*



Uruguay

Matias Victoria, *Salto*



ORIGINAL ARTICLE

27

Bifunctional staining for *ex vivo* determination of area at risk in rabbits with reperfused myocardial infarction

Feng Y, Ma ZL, Chen F, Yu J, Cona MM, Xie Y, Li Y, Ni Y

APPENDIX I-V Instructions to authors

ABOUT COVER Editorial Board Member of *World Journal of Methodology*, Monica Neagu, PhD, Associate Professor, Head of Immunobiology Laboratory, Victor Babes National Institute of Pathology, 99-101 Splaiul Independentei, sect 5, 050096 Bucharest, Romania

AIM AND SCOPE *World Journal of Methodology (World J Methodol, WJM, online ISSN 2222-0682, DOI: 10.5662)* is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

The primary task of *WJM* is to rapidly publish high-quality original articles, reviews, and commentaries that deal with the methodology to develop, validate, modify and promote diagnostic and therapeutic modalities and techniques in preclinical and clinical applications. *WJM* covers topics concerning the subspecialties including but not exclusively anesthesiology, cardiac medicine, clinical genetics, clinical neurology, critical care, dentistry, dermatology, emergency medicine, endocrinology, family medicine, gastroenterology and hepatology, geriatrics and gerontology, hematology, immunology, infectious diseases, internal medicine, obstetrics and gynecology, oncology, ophthalmology, orthopedics, otolaryngology, radiology, serology, pathology, pediatrics, peripheral vascular disease, psychiatry, radiology, rehabilitation, respiratory medicine, rheumatology, surgery, toxicology, transplantation, and urology and nephrology.

INDEXING/ABSTRACTING *World Journal of Methodology* is now indexed in Digital Object Identifier.

FLYLEAF I-III Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xin-Xin Che*
Responsible Electronic Editor: *Ya-Jing Lu*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Xue-Mei Cui*

NAME OF JOURNAL
World Journal of Methodology

ISSN
 ISSN 2222-0682 (online)

LAUNCH DATE
 September 26, 2011

FREQUENCY
 Quarterly

EDITOR-IN-CHIEF
Yicheng Ni, MD, PhD, Professor, Department of Radiology, University Hospitals, KU, Leuven, Herestraat 49, B-3000, Leuven, Belgium

EDITORIAL OFFICE
 Jin-Lei Wang, Director
 Xiu-Xia Song, Vice Director

World Journal of Methodology
 Room 903, Building D, Ocean International Center,
 No. 62 Dongsihuan Zhonglu, Chaoyang District,
 Beijing 100025, China
 Telephone: +86-10-59080039
 Fax: +86-10-85381893
 E-mail: wjg@wjgnet.com
<http://www.wjgnet.com>

PUBLISHER
 Baishideng Publishing Group Co., Limited
 Flat C, 23/F, Lucky Plaza, 315-321 Lockhart Road,
 Wanchai, Hong Kong, China
 Fax: +852-65557188
 Telephone: +852-31779906
 E-mail: bpgoffice@wjgnet.com
<http://www.wjgnet.com>

PUBLICATION DATE
 September 26, 2013

COPYRIGHT

© 2013 Baishideng. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

INSTRUCTIONS TO AUTHORS

Full instructions are available online at http://www.wjgnet.com/2222-0682/g_info_20100722180909.htm

ONLINE SUBMISSION

<http://www.wjgnet.com/esp/>

Bifunctional staining for *ex vivo* determination of area at risk in rabbits with reperfused myocardial infarction

Yuanbo Feng, Zhan-Long Ma, Feng Chen, Jie Yu, Marlein Miranda Cona, Yi Xie, Yue Li, Yicheng Ni

Yuanbo Feng, Feng Chen, Jie Yu, Marlein Miranda Cona, Yicheng Ni, Theragnostic Laboratory, Department of Imaging and Pathology, Biomedical Sciences Group, 3000 KU Leuven, Belgium

Zhan-Long Ma, Departments of Radiology, the First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, Jiangsu Province, China

Yi Xie, Departments of Electronics and Information System (ELIS), Ghent University, Sint-Pietersnieuwstraat 25, 9000 Gent, Belgium

Yue Li, Lab of Translational Medicine, Jiangsu Academy of Traditional Chinese Medicine, nanjing 210028, Jiangsu Province, China

Yicheng Ni, Radiology Section, University Hospitals, 3000 Leuven, Belgium

Author contributions: All authors made a substantial contribution to the conception and design of the manuscript, drafting the article or revising it.

Supported by The awarded grants of the KU Leuven Molecular Small Animal Imaging Center MoSAIC (KUL EF/05/08); the Center of Excellence *in vivo* Molecular Imaging Research (IMIR) of KU Leuven; a EU Project Asia-Link CfP 2006-Europe Aid/123738/C/ACT/Multi-Proposal, No. 128-498/111; and Jiangsu Province Natural Science Foundation, China, No. BK2010594

Correspondence to: Yicheng Ni, MD, PhD, Professor, Radiology Section, University Hospitals, KU Leuven Herestraat 49, 3000 Leuven, Belgium. yicheng.ni@med.kuleuven.be
Telephone: +32-16-330165 Fax: +32-16-343765
Received: July 12, 2013 Revised: July 16, 2013
Accepted: August 16, 2013
Published online: September 26, 2013

Abstract

AIM: To develop a method for studying myocardial area at risk (AAR) in ischemic heart disease in correlation with cardiac magnetic resonance imaging (cMRI).

METHODS: Nine rabbits were anesthetized, intubated and subjected to occlusion and reperfusion of the left circumflex coronary artery (LCx) to induce myocardial infarction (MI). ECG-triggered cMRI with delayed en-

hancement was performed at 3.0 T. After euthanasia, the heart was excised with the LCx re-ligated. Bifunctional staining was performed by perfusing the aorta with a homemade red-iodized-oil (RIO) dye. The heart was then agar-embedded for *ex vivo* magnetic resonance imaging and sliced into 3 mm-sections. The AAR was defined by RIO-staining and digital radiography (DR). The perfusion density rate (PDR) was derived from DR for the AAR and normal myocardium. The MI was measured by *in vivo* delayed enhancement (iDE) and *ex vivo* delayed enhancement (eDE) cMRI. The AAR and MI were compared to validate the bifunctional straining for cardiac imaging research. Linear regression with Bland-Altman agreement, one way-ANOVA with Bonferroni's multiple comparison, and paired t tests were applied for statistics.

RESULTS: All rabbits tolerated well the surgical procedure and subsequent cMRI sessions. The open-chest occlusion and close-chest reperfusion of the LCx, double suture method and bifunctional staining were successfully applied in all animals. The percentage MI volumes globally ($n = 6$) and by slice ($n = 25$) were $36.59\% \pm 13.68\%$ and $32.88\% \pm 12.38\%$ on iDE, and $35.41\% \pm 12.25\%$ and $32.40\% \pm 12.34\%$ on eDE. There were no significant differences for MI determination with excellent linear regression correspondence ($r_{\text{global}} = 0.89$; $r_{\text{slice}} = 0.9$) between iDE and eDE. The percentage AAR volumes globally ($n = 6$) and by slice ($n = 25$) were $44.82\% \pm 15.18\%$ and $40.04\% \pm 13.64\%$ with RIO-staining, and $44.74\% \pm 15.98\%$ and $40.48\% \pm 13.26\%$ by DR showing high correlation in linear regression analysis ($r_{\text{global}} = 0.99$; $r_{\text{slice}} = 1.0$). The mean differences of the two AAR measurements on Bland-Altman were almost zero, indicating RIO-staining and DR were essentially equivalent or inter-replaceable. The AAR was significantly larger than MI both globally and slice-by-slice ($P < 0.01$). After correction with the background and the blank heart without bifunctional staining ($n = 3$), the PDR for the AAR and normal myocardium was $32\% \pm 15\%$ and $35.5\% \pm 35\%$, respectively,

which is significantly different ($P < 0.001$), suggesting that blood perfusion to the AAR probably by collateral circulation was only less than 10% of that in the normal myocardium.

CONCLUSION: The myocardial area at risk in ischemic heart disease could be accurately determined post-mortem by this novel bifunctional staining, which may substantially contribute to translational cardiac imaging research.

© 2013 Baishideng. All rights reserved.

Key words: Reperfused; Acute myocardial infarction; Rabbit model; Cardiac magnetic resonance imaging; Oil-red-o dye; Iodized oil

Core tip: For developing therapeutic procedures/drugs aimed at modulating infarct size after coronary artery disease, it is important not only to measure myocardial infarction but also to know the extent of area at risk (AAR). However, determination of the AAR both *in vivo* and *ex vivo* can be challenging, and controversial. In this experiment we sought to develop a reliable method to accurately localize the culprit coronary occlusion for postmortem verification after *in vivo* cardiac magnetic resonance imaging and to establish a new bifunctional staining as a standard reference for *ex vivo* area at risk identification, which may substantially contribute to translational cardiac imaging research.

Feng Y, Ma ZL, Chen F, Yu J, Cona MM, Xie Y, Li Y, Ni Y. Bifunctional staining for *ex vivo* determination of area at risk in rabbits with reperfused myocardial infarction. *World J Methodol* 2013; 3(3): 27-38 Available from: URL: <http://www.wjgnet.com/2222-0682/full/v3/i3/27.htm> DOI: <http://dx.doi.org/10.5662/wjm.v3.i3.27>

INTRODUCTION

Acute occlusion of a coronary artery initiates an expanding process of myocardial infarction (MI) and this process ends in complete necrosis of the myocardial tissue within the perfusion bed if without a prompt therapeutic intervention. To develop therapeutic procedures and/or drugs aimed at modulating infarct size, it is very important not only to measure the MI size but also to know the extent of perfusion defect zone after coronary occlusion, which is also known as the area at risk (AAR) of myocardium^[1]. Since the AAR includes both infarcted/nonviable and viable/salvageable myocardium, detection of the AAR may provide an accurate index in clinical practice and preclinical research for diagnostic, therapeutic and prognostic assessment of ischemic heart disease^[2,3]. To define the AAR by both *in vivo* and *ex vivo* imaging can be challenging. Currently, the most widely used methods for *in vivo* AAR identification are contrast enhanced

computed tomography^[4] or cardiac magnetic resonance imaging (cMRI)^[5], radionuclide perfusion imaging^[6], and contrasted echocardiography^[7]. However, determination of the AAR proves difficult and controversial in clinical cardiology^[8]. The T2-weighted cMRI may highlight myocardial edema and therefore often overestimate infarct size, and sestamibi single photon emission computed tomography is limited by its low spatial resolution and radioactive nature. Compared to the AAR, MI can be evaluated *in vivo* by delayed enhancement (DE) cMRI, an established technique that is widely accepted in clinic to reveal acute and chronic MI in patients^[9]. This technique has been validated in animal models with reperfused MI using extracellular contrast agents^[10,11].

Experimentally, to validate *in vivo* imaging observations, a variety of *ex vivo* methods have been developed and attempted to directly visualize and quantify the AAR and MI in animal experiments, because exact postmortem detection of myocardial AAR and MI is deemed necessary as the gold reference. A few decades ago, some investigators tried to assess the AAR through postmortem intracoronary injections of colored industrial dyes^[12] or barium gels^[13], which stained the normal myocardium but left the AAR unstained. However, highly viscous injectants and undetermined pressure could lead to inaccurate AAR delineation. Nowadays, widespread techniques used for determination of coronary perfusion or AAR are blue dyes (typically Evans blue) and radiolabeled or colored microspheres, with which the heart is perfused at the end of experiments after re-occlusion of the coronary artery^[1,14,15]. Triphenyltetrazolium chloride (TTC) histochemical staining is usually combined with a blue dye for simultaneous visualization of normal myocardium, AAR and MI^[16]. These methods have their limitations. For instance, the most commonly used water-soluble blue dye Evans-blue may precipitate out of solution and affect the subsequent TTC staining^[17]. These dyes are also prone to smearing during slicing, resulting in an ambiguous border definition^[17]. The radiolabeled microspheres need the complex procedures and operators have to be exposed to radiation, in addition to the difficulty in some institutions due to unavailable nuclear facilities. The colored microspheres require tissue lyses for counting without morphometry. Therefore, such analyses still remain technically challenging.

To precisely recognize the location of previously occluded coronary branch is crucial for subsequent *ex vivo* calculation of AAR size. Few study detailed the technical information for accurate coronary re-ligation^[18].

Given the suboptimal features of above-mentioned dyes and microspheres for visualizing the AAR in pre-clinical study, we sought to: (1) develop a reliable method to accurately localize the previous coronary occlusion site for postmortem re-ligation; (2) establish a new bifunctional staining as standard reference for *ex vivo* AAR evaluation; (3) validate the method by quantitative measurement and morphometry; and (4) compare the AAR defined by the new staining to the cMRI findings at a 3.0




Figure 1 Flow chart of experimental protocol. cMRI: Cardiac magnetic resonance imaging; DE: Delayed enhancement; RIO: Red-iodized-oil; DR: Digital radiography; HE: Hematoxylin-eosin.

T clinic magnet with histological verifications.

The above goals could have been realized only when has a prior-established methodology, *i.e.*, an occlusion/reperfusion based rabbit model of acute MI and a technical platform for pre- and postmortem imaging colocalization now become available^[19,20]. The rabbit as a mediate size experimental animal can be easily handled, with favorable cost-effectiveness and compatibility to clinically available MRI facilities with the entire heart section includable in a standard histological glass slide. The resulted outcomes are deemed pertinent to human patients^[19,21].

MATERIALS AND METHODS

This experimental study was carried out according to a protocol (Figure 1) that was approved by the Animal Care and Use Committee of KU Leuven, Belgium.

Preparation of red iodized oil dye

The custom-made bifunctional dye of red iodized oil (RIO) was formulated by diluting 20 mg oil-red-O dye (Sigma-Aldrich) in 100 mL of any brand of commercially available iodized oil such as Lipiodol ultra fluid (Guerbet, France), which is also known as ethiodized oil consisting of about 30%-40% iodine and poppyseed oil originally used as a radio-opaque contrast agent to outline structures in radiological investigations or in combination for transarterial chemoembolization of malignant tumors^[22,23].

Animal model of acute reperfused myocardial infarction

A total of 9 male New Zealand white rabbits (Animal House, KU Leuven, Belgium), weighing 3.2-4.0 kg, were included in this study. Animals were housed under standard laboratory conditions.

The model of acute reperfused MI was prepared by slight modification on a previously introduced method^[19]. After sedation, endotracheal intubation and mechanical ventilation, the rabbit received intravenous (IV) injection of pentobarbital (Nembutal, Sanofi Sante Animale, Brussels, Belgium) at 40 mg/kg per hour to maintain anesthesia during the open-chest operation to dissect the pericardium and expose the left circumflex coronary branch (LCx). For making a removable coronary ligation *in vivo* and precise re-ligation *ex vivo*, we used a 1/2 circle shape triangular needle (Sutura, Inc. Fountain Valley, CA, United States) with spring eyes at the end (Figure 2A).

Two silk sutures could be easily placed through the separate eyes (Figure 2B): the thicker one (2-0) was used for the LCx ligation that could be removed for reperfusion and the thinner one (5-0) was spared for later *ex vivo* LCx re-occlusion in order to perform postmortem bifunctional staining (Figure 2C). The acute reperfused MI was induced by tying the thicker suture with a detachable single knot for 90 min, and LCx reperfusion was achieved by pulling the exteriorized end of suture in the closed-chest condition as detailed previously^[19]. The ECG (Accusync[®] 71, Milford, Connecticut, Unites States) was monitored to confirm the formation of MI and to detect the occurrence of arrhythmia, which was treated by IV dose of Xylocaine (AstraZeneca SA, Brussels, Belgium) at 2-4 mg/kg if needed. Buprenorfine hydrochloride (Temgesic; Schering-Plough, Brussels, Belgium) of 0.216 mg was intramuscularly injected to relieve pain. All rabbits were allowed to recover and kept alive until cMRI scanning 24 h after LCx reperfusion.

Cardiac magnetic resonance imaging

The rabbit was gas-anesthetized through a mask with 2% isoflurane in the mixture of 20% oxygen and 80% room air and placed supinely in a plastic holder. Using a commercial 8-channel phased array knee coil, the rabbit was subjected to cMRI at a 3.0 T clinical MRI scanner (Trio, Siemens, Erlangen, Germany) with a maximum gradient capability of 45 mT/m. The ECG and respiration were triggered and gated by a Small Animal Monitoring System (SA Instruments, Inc. Stony Brook, New York, United States). Two ECG surface electrodes were attached to the shaved thorax skin with apparently apical pulse and the left leg. The respiration control sensor was attached on the middle of the rabbit abdomen. All data were acquired during free breathing of the animal. After determining the cardiac axes with localizers, the DE cMRI using T1-weighted 3-dimensional segmented k-space inversion recovery turbo fast low angle shot sequence was performed 20 min after intravenous administration of 0.2 mmol/kg Gd-DOTA (Dotarem, Guerbet, France). Short-axis DE cMRI was acquired to depict the presence, location, and extent of the MI. The imaging parameters were: TR: 396 ms; TE: 1.54 ms; TI: 360 ms; FOV: 240 × 180 mm²; FA: 15°; and in-plane resolution: 1.1 × 0.8 mm². The *ex vivo* higher resolution DE-cMRI was also obtained immediately after animal sacrifice using the same MRI unit with a wrist coil as previously described^[19]. The DE cMRI using an extracellular nonspecific contrast agent has been ap-




Figure 2 Double suture method in rabbit model of reperfused myocardial infarction. A: A 1/2 circle shape triangular needle has spring eyes at the end; B: Two silk sutures were placed through separate eyes; C: The thicker suture (2-0) was used for the left circumflex coronary artery (LCx) ligation, which would be removed for reperfusion, and the thinner one (5-0) was spared for later *ex vivo* LCx re-occlusion in order to perform postmortem bifunctional staining.

plied in both animal MI models and clinical patients as a gold standard technique for identification and quantification of the MI^[10,11]. Therefore, the final MI size was also defined by *in vivo* and *ex vivo* DE-cMRI in this study.

Postmortem bifunctional staining

Bifunctional staining of the RIO dye refers to: (1) visualization, location and delineation of the AAR by using its red staining function for further morphometric quantification; and (2) microangiographic examination of the AAR by using the digital radiography (DR) function to compare the perfusion density rate (PDR) between the AAR and normal myocardium. This staining served as a postmortem index for regional myocardial blood flow. Briefly, after the last *in vivo* cMRI, the rabbit was IV injected with Heparin at 300 IU/kg to prevent coagulation. Under deep anesthesia and thoracotomy, the heart was excised with a section of the aortic arch isolated and pericardial tissue trimmed. As shown in Figure 3A, a plastic catheter filled with 0.9% saline was inserted into the aorta and anchored with its tip 1 cm above the aortic valves. Care was taken to avoid air bubbles entering the catheter that was connected to a 10 mL syringe fixed on the injection bump (BD PILOT, Becton Dickinson Infusion System, France). Under a perfusion pressure of 100 mmHg, 10 mL saline was infused until the eluate from the coronary sinus became clear. The heart was rinsed to wash out remaining blood. Then, the 5-0 suture spared at the coronary occlusion site during open-chest operation was tightened for causing re-occlusion, and 4 mL of RIO dye (Figure 3B) was infused through the aortic catheter

for 15 min under the same pressure by using the same pump as mentioned above. The infusion was stopped when the normal myocardium was completely stained red by the RIO dye (Figure 3C). Upon this perfusion staining technique with the LCx re-ligated, the normal myocardium stained brick red and the AAR remained uncolored. Afterwards, the heart was imbedded in agar solution for *ex vivo* cMRI, followed by serial sectioning into 6-8 slices of 3.0 mm thickness to match with the corresponding short axis cMRI images. Such stained heart sections were exposed by DR with a mammographic unit (Embrace; Agfa-Ge-vaert, Mortsel, Belgium) at 25 KV and 18 mA, and photographed by a digital camera before and after 24 h of fixation with 10% formalin. The fixed heart sections were imbedded into paraffin and processed for histology with 5 micron thick hematoxylin-eosin (HE) stained slices for microscopic inspection.

Imaging analysis

The MI size on cMRI was determined in consensus by three authors with the built-in software of Siemens workstation (SyngoMR A30). To facilitate cardiac morphometric comparisons with different imaging methods, the dimension was calculated as a value relative to the entire left ventricular myocardium. The MI size (%) on DE cMRI was derived semi-automatically by computer to count all enhanced pixels with the signal intensity higher than two standard deviations above the mean of image intensities in the remote NM, which were divided by all ventricular pixels on the same short-axis image. Digital photographs of RIO-staining sections and DR images



Figure 3 Bifunctional staining methods. A: A plastic catheter filled with saline was inserted into the aorta and anchored with its tip 1 cm above the aortic valves, which was connected to a 10 mL syringe fixed in the injection bump. The heart was gently rinsed to wash out remaining blood, then the left circumflex coronary artery was re-ligated, and 2-4 mL of red iodized oil (RIO) dye was infused; B: Homemade RIO dye; C: Lateral view of the RIO perfused heart. The perfusion of RIO dye was stopped when the normal myocardium was stained completely scarlet red, while the area at risk remained unstained.

were transferred to a personal computer for planimetric analysis by using Image J 1.38x software (Research Services Branch, NIH, Bethesda, MD, United States). The AAR defined as non-stained area by RIO-dye and non-opaque area by DR was contoured with consensus on the computer screen. Due to partial volume effect and fatty tissue interference on DE cMRI, the apical and basal slices were excluded and the remaining slices ($n = 25$) obtained from 6 rabbits were used for the comparisons of the corresponding bifunctional staining sections.

Perfusion density rate measurement

The measurement of perfusion density rate (PDR%) measurement was performed on DR images of the heart sections using the same Image J 1.38x software. The blank myocardial density refers to the DR density of the heart tissues from control group ($n = 3$) without RIO dye staining. The AAR of low density and the normal myocardium of high density were delineated in all sections ($n = 25$) with an operator-defined region of interest. The mean gray value (GV) of all sections were automatically generated and normalized by the background GV. PDR% refers to the increased perfusion density relative to background, which was calculated by the following formula: $PDR\% = (GV_{\text{region of interest}} - GV_{\text{blank myocardial density}}) / GV_{\text{background}} \times 100$.

Statistical analysis

Numerical data were expressed as mean \pm SD. Comparisons among multiple factors were performed using

one way ANOVA, followed by the Bonferroni's test to identify any differences between each two techniques. All tests were two tailed. The correlations were tested by Spearman's method. The linear regression and the means of Bland-Altman analysis were used for correlation and agreement, respectively. Correlations were described by the correlation coefficient with 95% CIs. A difference was considered statistically significant if the P value was less than 0.05. The paired student t test was used for comparison of the PDR between the AAR and MI. The statistical analyses were performed with Analyse-it[®] 2.14 for Excel and GraphPad Prisma[®] 5.0.

RESULTS

General outcomes

All animals survived the anesthesia, surgical procedures for inducing acute reperfused MI and subsequent cMRI. As one of the critical steps, the double suture method was successfully applied in all animals, which ensured later bifunctional staining. The normal myocardium from all rabbits was well perfused by the RIO dye. Figure 4 demonstrated a case with a large reperfused MI by different techniques. The hyperenhanced transmural MI appeared similarly on both iDE and eDE (Figure 4A, B), which was somewhat smaller than the AAR as an unstained region by RIO (Figure 4C) and non-opacified region on DR (Figure 4D). With this bifunctional staining, the large haemorrhagic MI appeared brown greyish (Figure 4C) after overnight Formalin fixation. The myocardial necrosis




Figure 4 An example of a reperfused hemorrhagic myocardial infarction (arrow) shown by cardiac magnetic resonance imaging and the area at risk demonstrated with bifunctional staining method. A: The hyperenhanced transmural myocardial infarction (MI) was seen at the lateral wall on *in vivo* delay enhancement (DE) cardiac magnetic resonance imaging (cMRI); B: The *ex vivo* DE cMRI was highly correspondent with A; C: In contrast to the normal myocardium with red staining, the area at risk (AAR) was shown as an unstained region, on which the brown grayish area indicates a large intramural hemorrhagic infarction after the fixation by Formalin; D: On digital radiography (DR), the AAR was shown as non-opacified region in contrast to the opacified normal myocardium. Notice that the AAR defined by red iodized oil-staining (RIO-staining) in C and DR in D was somewhat larger than the MI defined by *in vivo* DE cMRI in A and *ex vivo* DE cMRI in B; E: The hematoxylin-eosin (HE) stained macroscopic view was obtained from the corresponding histological section of A, B, C, and D; F: Photomicroscopic view of the HE stained slice (magnification, $\times 100$) confirmed the presence of myocardial necrosis with hemorrhage and tissue reaction. h: Hemorrhagic infarction; n: Adjacent normal myocardium with inflammatory infiltration.

with haemorrhage was finally confirmed by macro- and microscopic views of HE stained slice (Figure 4E, F).

Magnetic resonance imaging findings

The location and extent of the MI were clearly shown as the hyperenhanced region on DE cMRI in all cases. The percentage MI sizes globally ($n = 6$) and slice-by-slice ($n = 25$) were 36.59% and 35.41% on *in vivo* DEcMRI (iDE), and 32.88% and 32.40% on *ex vivo* DEcMRI (eDE). There was no significant difference between iDE and eDE. Linear regression analyses showed an excellent correlation both globally and slice-by-slice between MI volumes on iDE and eDE ($r = 0.89, 0.98$) (Figure 5A, B). By Bland-Altman analysis, there was a 1.2% bias with 95% CIs of 2.4% to 4.7% in global heart (Figure 5C) and 0.5% bias with 95% CIs of 2.6% to 3.6% by slice (Figure 5D), indicating high agreement of the two measurement methods.

Bifunctional staining findings with red-iodized-oil dye

The RIO dye was successfully formulated (Figure 3B). It showed homogenous distribution into the accessible cardiac tissues. After staining, the normal myocardium appeared scarlet red (Figure 3C) and rose red (Figure 4C)

before and after formalin fixation and as more opacified region on DR images (Figure 4D), whereas the AAR showed as non-RIO-stained region on heart slices (Figure 4C) and the less opacified region on DR image (Figure 4D). By bifunctional staining, the percentage AAR_{global} was $44.8\% \pm 15.18\%$ and $44.74\% \pm 15.98\%$, and percentage AAR_{slice} was $40.04\% \pm 13.64\%$ and $40.48\% \pm 13.26\%$ by RIO-staining and DR, respectively. There was no significant difference between RIO-staining and DR ($P = 0.9$). Linear regression analyses showed an excellent correlation both globally and slice-by-slice between AAR volumes defined by RIO-staining and DR ($r = 0.99, 1.0$) (Figure 6A, B). The limits of Bland-Altman agreement were 3.2%-3.0% (Figure 6C) by slice and 2.3%-1.8% (Figure 6D) in global measurements with RIO-staining and DR respectively. The mean difference was almost zero, indicating a very high agreement between RIO-staining and DR techniques.

Comparing different techniques

The MI quantified from both iDE and eDE cMRI were significantly smaller than the $AAR_{RIO-staining}$ and AAR_{DR} with bifunctional staining ($P < 0.01$; Figure 7), confirming that the final MI was smaller than ischemic region.




Figure 5 The linear correlation (above) and Bland-Altman analyses (bottom) plots comparing the myocardial infarction on *in vivo* and *ex vivo* delayed enhancement magnetic resonance imaging. The plots graph displayed a good correlation between MI measured with *in vivo* delayed enhancement (iDE) and *ex vivo* delayed enhancement (eDE) on global (A) and slices (B). Plots of differences in myocardial infarction on global (C) and slices (D) were indicative of high agreement between iDE and eDE.

However, the MI on eDE-cMRI correlated well with AAR_{RIO-staining} and AAR_{DR} (Figure 8), suggesting that the bifunctional staining with RIO dye could successfully delineate and characterize the AAR.

Perfusion density rate

After aortic infusion with the RIO dye while the LCx was re-ligated, the PDR of the normal myocardium and AAR became $354.89\% \pm 35.18\%$ and $32.28\% \pm 15.06\%$ relative to the equipment background. The PDR was significantly lower in the AAR, *i.e.*, only about $9.10\% \pm 3.93\%$ of the PDR in the normal myocardium ($P < 0.001$) (Figure 9), suggesting insufficient collateral coronary blood supply during the 90 min occlusion, leading to the rabbit model of reperfused MI.

DISCUSSION

We studied myocardial AAR in the rabbit heart after 90 min of LCx occlusion followed by reperfusion. The AAR refers to the myocardium without blood supply during coronary artery occlusion. The final MI was detected by *in vivo* and *ex vivo* DE cMRI. The main outcomes of the present study are: (1) the newly developed method of

bifunctional staining enabled reliable high-quality images; (2) both *in vivo* and *ex vivo* DE cMRI allowed visualization and quantification of the MI; (3) though measured with different methods, the dimension of the AAR was significantly larger than that of the MI, suggesting the potential of this method to help discriminate the well perfused normal myocardium from the non-perfused nonviable and/or less perfused by viable probably salvageable myocardium; and (4) the PDR was 10 times lower in the AAR compared to the normal myocardium, suggesting that the bifunctional RIO dye may facilitate not only morphometry but also perfusion quantification.

The animal models of reperfused MI have been extensively applied for cardiovascular research both in large and small animals. How to accurately re-ligate coronary artery branch to replicate the exact occlusion site prior to reperfusion appears crucial. The majority of the authors used the snare-loop method for coronary artery occlusion-reperfusion on the open-chest MI model with later postmortem vessel re-ligation^[24]. Other studies described re-occlusion of coronary branches with a balloon catheter under the close-chest conditions^[25]. However, there is a lack of detailed information about how to imitate postmortem the exact *in vivo* artery occlusion, which




Figure 6 The linear correlations (above) and Bland-Altman analyses (bottom) to compare the area at risk by red iodized oil-staining and digital radiography of the bifunctional staining. The plots showed a good correlation between the area at risk (AAR) measured with red iodized oil (RIO)-staining and digital radiography (DR) on global (A) and slices (B). Plots of the differences in AAR on global (C) and slices (D) were almost zero, indicating that RIO-staining and DR are essentially equivalent.




Figure 7 Comparisons between myocardial infarction and area at risk by different techniques. There were no significant differences between myocardial infarction *in vivo* delayed enhancement (MI *i*DE) and myocardial infarction *ex vivo* delayed enhancement (MI *e*DE) measured from cardiac magnetic resonance imaging in global (left) and slices (right). There were no significant differences between area at risk digital radiography (AR_{DR}) and area at risk red iodized oil-staining (AAR_{RIO-staining}) in global (left) and slices (right). The significant differences were observed on AR_{DR} vs MI *i*DE ($P < 0.01$); AR_{DR} vs MI *e*DE ($P < 0.01$); AAR_{RIO-staining} vs MI *i*DE ($P < 0.01$); AAR_{RIO-staining} vs MI *e*DE ($P < 0.01$). NS: Not significant.

is though a prerequisite for defining the AAR or ischemic area. We have previously introduced an effective method for *in vivo* LCx occlusion and reperfusion^[19]. In this study we modified that method by using the double sutures to

precisely co-localize LCx obstruction both *in vivo* and *ex vivo*. Within the same puncture, one suture was for *in vivo* coronary occlusion and reperfusion, and the other suture was left spared *in vivo* but tightened with a knot to re-




Figure 8 The linear correlations between *ex vivo* cardiac magnetic resonance imaging and bifunctional staining. The myocardial infarction (MI) measured by global (left) and slices (right) on *ex vivo* delayed enhancement cardiac magnetic resonance imaging corresponded well with area at risk by red iodized oil-staining (above) and digital radiography (bottom), confirming the bifunctional staining with RIO dye could successfully delineate and characterize the AAR. MI_{eDE}: Myocardial infarction *ex vivo* delayed enhancement; AAR_{RIO-staining}: Area at risk on red-iodized oil-staining; AAR_{DR}: Area at risk on digital radiography.




Figure 9 Comparison of perfusion density rate between area at risk and normal myocardium. Coronary artery occlusion caused a significant decrease of blood perfusion in ischemic region compared to non-ischemic region ($P < 0.001$), resulted in a difference over 10 times in-between. AAR: Area at risk.

occlude the coronary branch *ex vivo*. This double suture method was successfully validated in all animals, which is a critical step to ensure later bifunctional staining to obtain the desired results as presented.

In the cardiac imaging research on the ischemic heart

disease using animal hearts, a most crucial issue is adequate staining of the AAR and discrimination between risk and non-risk zones, because a correctly defined borderline between the ischemic and necrotic zones will have a direct impact on MI diagnosis and therapeutic interventions. In this article we described a new bifunctional staining method to define the AAR, which, to our best knowledge, has not been reported in the literature. Function 1 is to visualize the normal myocardium in red color but the AAR uncolored utilizing the oil-red-o component of the custom-made RIO dye, which facilitates morphometric delineation, quantification and comparison; whereas function 2 is to enable visualization and volumetric density measurement of the non-opacified normal myocardium and the opacified AAR by utilizing the iodized oil component of the RIO dye for making DR to extrapolate, quantify and evaluate the difference in hemodynamic features such as coronary vessel density, interstitial distribution space and/or regional myocardial blood flow/volume between the normal and ischemic myocardium.

There have been some methods reported in the literature for postmortem delineation of the AAR. Coronary infusion of hydrophilic Evans-blue solution is the most

common technique to stain the remote myocardium while the insulted coronary branch is re-ligated^[25-27]. Evans-blue is a water-soluble intravital dye with strong albumin binding capacity and has been used in hemodynamic studies for decades^[28,29]. More recently Evans-blue has been found with high necrosis avidity and used to clearly mark the well-reperfused necrotic tissues^[30-32]. Therefore, there is a risk of underestimation of the AAR due to contamination of the inwards diffused Evans-blue to the ischemic necrosis^[15]. Some other groups tried to use TTC for demarcating the AAR, however TTC perfusion induced severe tissue contraction, which may affect the geometry of heart and might prevent subsequent successful dye perfusion^[17]. Other studies used fluorescein dyes under dark background or radio- and color-labeled microspheres to define or quantify the AAR^[33-35]. However, all these methods are only unifunctional and/or lacking required accuracy. The custom-made bifunctional RIO dye as introduced in this study appears a much better alternative to Evans blue. The first component of RIO dye is oil-red-O, which is a stable lipophilic pigment and can be easily diluted in any lipid media such as the iodized oil as the second component of this dye. The distribution of the RIO dye in the cardiac tissue after intracoronary infusion seems only pressure dependent rather than being diffusible afterwards driven by its concentration gradient due to the fact that a hydrophobic dye exists in the hydrophilic environment of myocardium, resulting in a more accurate delineation of the borders of the AAR without infiltration of the dye into the adjacent ischemic region.

Suspension of barium sulphate has also been used for postmortem coronary angiography^[13,36]. However, the heavy particles tended to precipitate in its water media, leading to suboptimal perfusion to vascular bed with smaller vessels. As shown in this study, the second component of iodized oil in the RIO dye solved the problem well in DR and its quantification. Thus, the golden combination of the two dye components facilitated successfully the bifunctional staining and enabled comprehensive AAR study.

We have gained the following experiences: (1) heparinizing the animal prior to sacrifice and rinsing the coronary bed with normal saline beforehand proved beneficial for the next bifunctional staining of the AAR by RIO dye perfusion; (2) controlling adequate pressure and observing epicardial red coloration during dye infusion were crucial for the success of procedure; and (3) fixing the heart sections with formalin overnight helped color differentiation between the normal myocardium (rose red) and AAR (gray or brown grayish depending on the degree of hemorrhage) and later planimetric quantification due to a clear borderline.

Myocardial blood volume (capillary bed) and myocardial blood flow can be determined by microsphere methods in animals after excision of the heart^[33,35]. Such methods, however, require cutting the myocardium into discrete samples, which may be a combination of nor-

mal tissue, border zone, hyperemic tissue, and severely ischemic tissue. Thus, the processing of selected tissue samples can bias the results as well as blur the exact relation to overall myocardial morphology. Although the degree of resolution for flow measurement could possibly be improved by cutting myocardium into smaller samples, this becomes tedious and impractical for studying flow throughout the heart. Besides, it is more difficult to get topographic information.

Using the PDR derived from microangiography on DR to indirectly evaluate vascular blood perfusion to viable and necrotic tissues has been reported^[37]. In our experiment, The PDR was significantly lower in AAR, which was about 9% of the normal myocardium. This finding is close to the results of Connelly's group on myocardium blood flow measured by radioactive microspheres on the similar animal setting^[38]. The other group showed that in the reperfusion MI dog model, myocardial samples with only mild (about 20%-30%) reductions in myocardial blood flow compared to non-ischemic regions^[39], which appears higher than our results probably due to the richer collaterals of coronary artery in dogs than in rabbit^[40]. The application of this new staining method on our rabbit model was successful and can be translated to other species.

Accurate quantitative measurement of MI size is an important aspect of cardiovascular research. The *in vivo* cMRI for accurate evaluation of MI has been described previously in rabbit models^[19]. In this study we have performed the high resolution *ex vivo* cMRI with extensive postmortem evaluations on rabbit hearts, which were supported by histological staining and consistent to *in vivo* cMRI. The bifunctional staining could be incorporated into the study using clinically available MRI facilities to acquire outcomes that are more pertinent to human patients.

Study limitations

First, the AAR was demarcated by intracoronarily infusing the heart with the RIO dye after local re-occlusion. Such a procedure was time-consuming with possible technical failure to obtain homogeneous staining of all accessible normal myocardium. Secondly, the postmortem dye distribution may differ from *in vivo* blood perfusion of the normal myocardium when the related artery is occluded, because normal coronary flow is influenced by the intraventricular pressure so the flow in postmortem infusion may not exactly simulate the *in vivo* flow pattern. Furthermore, in this experiment by using RIO dye, we could achieve accurate delineation of the AAR postmortem, but we could hardly discriminate the MI from any ischemic but still viable tissues within the AAR. Considering these drawbacks, we have to further optimize this experimental setting for determination of both AAR and MI under both *in vivo* and *ex vivo* conditions.

In conclusion, this article introduced a novel bifunctional staining method to accurately visualize and quantify AAR postmortem, which was successfully applied in rab-

bit models with ischemia-reperfusion MI. The key advantages include a newly developed bifunctional RIO dye, a new *ex vivo* staining method with greater color intensity in the remote normal myocardium and improved contrast for border delineation to obtain both morphometric and functional information for reliable AAR measurement. This methodology is deemed of high research values and to substantially contribute to the translational research in cardiovascular sciences.

ACKNOWLEDGMENTS

The corresponding author Yicheng Ni is currently a Bayer Lecture Chair holder.

COMMENTS

Background

For developing therapeutic procedures/drugs aimed at modulating infarct size after coronary artery disease, it is important not only to measure myocardial infarction but also to know the extent of area at risk (AAR). However, determination of the AAR both *in vivo* and *ex vivo* can be challenging, and controversial.

Innovations and breakthroughs

In this experiment the authors sought to develop a reliable method to accurately localize the culprit coronary occlusion for postmortem verification after *in vivo* cardiac magnetic resonance imaging and to establish a new bifunctional staining as a standard reference for *ex vivo* area at risk identification, which may substantially contribute to translational cardiac imaging research.

Applications

The myocardial area at risk in ischemic heart disease could be accurately determined postmortem by this novel bifunctional staining, which may substantially contribute to translational cardiac imaging research.

Peer review

This is a conscientious and carefully written preclinical paper.

REFERENCES

- 1 Aletras AH, Tilak GS, Natanzon A, Hsu LY, Gonzalez FM, Hoyt RF, Arai AE. Retrospective determination of the area at risk for reperfused acute myocardial infarction with T2-weighted cardiac magnetic resonance imaging: histopathological and displacement encoding with stimulated echoes (DENSE) functional validations. *Circulation* 2006; **113**: 1865-1870 [PMID: 16606793 DOI: 10.1161/Circulationaha.105.576025]
- 2 Berry C, Kellman P, Mancini C, Chen MY, Bandettini WP, Lowrey T, Hsu LY, Aletras AH, Arai AE. Magnetic resonance imaging delineates the ischemic area at risk and myocardial salvage in patients with acute myocardial infarction. *Circ Cardiovasc Imaging* 2010; **3**: 527-535 [PMID: 20631034 DOI: 10.1161/Circimaging.109.900761]
- 3 Darsee JR, Kloner RA, Braunwald E. Demonstration of lateral and epicardial border zone salvage by flurbiprofen using an *in vivo* method for assessing myocardium at risk. *Circulation* 1981; **63**: 29-35 [PMID: 7002363 DOI: 10.1161/01.CIR.63.1.29]
- 4 Mewton N, Rapacchi S, Augeul L, Ferrera R, Loufouat J, Bousset L, Micolich A, Rioufol G, Revel D, Ovize M, Croisille P. Determination of the myocardial area at risk with pre- versus post-reperfusion imaging techniques in the pig model. *Basic Res Cardiol* 2011; **106**: 1247-1257 [PMID: 21874556 DOI: 10.1007/s00395-011-0214-8]
- 5 Friedrich MG, Abdel-Aty H, Taylor A, Schulz-Menger J, Messroghli D, Dietz R. The salvaged area at risk in reperfused acute myocardial infarction as visualized by cardiovascular magnetic resonance. *J Am Coll Cardiol* 2008; **51**: 1581-1587 [PMID: 18420102 DOI: 10.1016/j.jacc.2008.01.019]
- 6 Ceriani L, Verna E, Giovannella L, Bianchi L, Roncari G, Tarolo GL. Assessment of myocardial area at risk by technetium-99m sestamibi during coronary artery occlusion: comparison between three tomographic methods of quantification. *Eur J Nucl Med* 1996; **23**: 31-39 [PMID: 8586099]
- 7 Villanueva FS, Glasheen WP, Sklenar J, Kaul S. Characterization of spatial patterns of flow within the reperfused myocardium by myocardial contrast echocardiography. Implications in determining extent of myocardial salvage. *Circulation* 1993; **88**: 2596-2606 [PMID: 8252670 DOI: 10.1161/01.CIR.88.6.2596]
- 8 Arai AE, Leung S, Kellman P. Controversies in cardiovascular MR imaging: reasons why imaging myocardial T2 has clinical and pathophysiologic value in acute myocardial infarction. *Radiology* 2012; **265**: 23-32 [PMID: 22993218 DOI: 10.1148/radiol.12112491]
- 9 Bondarenko O, Beek AM, Hofman MB, Kühl HP, Twisk JW, van Dookum WG, Visser CA, van Rossum AC. Standardizing the definition of hyperenhancement in the quantitative assessment of infarct size and myocardial viability using delayed contrast-enhanced CMR. *J Cardiovasc Magn Reson* 2005; **7**: 481-485 [PMID: 15881532]
- 10 Oshinski JN, Yang Z, Jones JR, Mata JF, French BA. Imaging time after Gd-DTPA injection is critical in using delayed enhancement to determine infarct size accurately with magnetic resonance imaging. *Circulation* 2001; **104**: 2838-2842 [PMID: 11733404 DOI: 10.1161/hc4801.100351]
- 11 Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, Bundy J, Finn JP, Klocke FJ, Judd RM. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. *Circulation* 1999; **100**: 1992-2002 [PMID: 10556226 DOI: 10.1161/01.CIR.100.19.1992]
- 12 Lowe JE, Reimer KA, Jennings RB. Experimental infarct size as a function of the amount of myocardium at risk. *Am J Pathol* 1978; **90**: 363-379 [PMID: 623206]
- 13 Ohzono K, Koyanagi S, Urabe Y, Harasawa Y, Tomoike H, Nakamura M. Transmural distribution of myocardial infarction: difference between the right and left ventricles in a canine model. *Circ Res* 1986; **59**: 63-73 [PMID: 3731411 DOI: 10.1161/01.RES.59.1.63]
- 14 Hale SL, Alker KJ, Kloner RA. Evaluation of nonradioactive, colored microspheres for measurement of regional myocardial blood flow in dogs. *Circulation* 1988; **78**: 428-434 [PMID: 3396179]
- 15 Redel A, Jazbutyte V, Smul TM, Lange M, Eckle T, Eltzschig H, Roewer N, Kehl F. Impact of ischemia and reperfusion times on myocardial infarct size in mice *in vivo*. *Exp Biol Med* (Maywood) 2008; **233**: 84-93 [PMID: 18156310 DOI: 10.3181/0612-RM-308]
- 16 Khalil PN, Siebeck M, Huss R, Pollhammer M, Khalil MN, Neuhof C, Fritz H. Histochemical assessment of early myocardial infarction using 2,3,5-triphenyltetrazolium chloride in blood-perfused porcine hearts. *J Pharmacol Toxicol Methods* 2006; **54**: 307-312 [PMID: 16580232 DOI: 10.1016/j.jvascn.2006.02.010]
- 17 Bohl S, Medway DJ, Schulz-Menger J, Schneider JE, Neubauer S, Lygate CA. Refined approach for quantification of *in vivo* ischemia-reperfusion injury in the mouse heart. *Am J Physiol Heart Circ Physiol* 2009; **297**: H2054-H2058 [PMID: 19820193 DOI: 10.1152/ajpheart.00836]
- 18 Rodrigues AC, Hataishi R, Ichinose F, Bloch KD, Derumeaux G, Picard MH, Scherrer-Crosbie M. Relationship of systolic dysfunction to area at risk and infarction size after ischemia-reperfusion in mice. *J Am Soc Echocardiogr* 2004; **17**: 948-953 [PMID: 15337959 DOI: 10.1016/j.echo.2004.05.014]
- 19 Feng Y, Xie Y, Wang H, Chen F, Ye Y, Jin L, Marchal G, Ni Y. A modified rabbit model of reperfused myocardial infarction for cardiac MR imaging research. *Int J Cardiovasc*

- Imaging* 2009; **25**: 289-298 [PMID: 19043805 DOI: 10.1007/s10554-008-9393-2]
- 20 **Feng Y**, Chen F, Xie Y, Wang H, Cona MM, Yu J, Li J, Bogaert J, Janssens S, Oyen R, Ni Y. Lipomatous metaplasia identified in rabbits with reperfused myocardial infarction by 3.0 T magnetic resonance imaging and histopathology. *BMC Med Imaging* 2013; **13**: 18 [PMID: 23815556 DOI: 10.1186/1471-2342-13-18]
- 21 **van der Laarse A**, van der Wall EE. Rabbit models: ideal for imaging purposes? *Int J Cardiovasc Imaging* 2009; **25**: 299-301 [PMID: 19085084 DOI: 10.1007/s10554-008-9401-6]
- 22 **Eurvilaichit C**. Lipiodol enhanced CT scanning of malignant hepatic tumors. *J Med Assoc Thai* 2000; **83**: 398-406 [PMID: 10808700]
- 23 **Kurokohchi K**, Deguchi A, Masaki T, Himoto T, Yoneyama H, Kobayashi M, Maeta T, Kiuchi T, Kohi F, Miyoshi H, Taminato T, Kuriyama S. Successful treatment of hypovascular advanced hepatocellular carcinoma with lipiodol-targeting intervention radiology. *World J Gastroenterol* 2007; **13**: 4398-4400 [PMID: 17708619]
- 24 **Higuchi T**, Taki J, Nakajima K, Kinuya S, Namura M, Tonomi N. Time course of discordant BMIPP and thallium uptake after ischemia and reperfusion in a rat model. *J Nucl Med* 2005; **46**: 172-175 [PMID: 15632049 DOI: 46/1/172]
- 25 **Dębiński M**, Buszman PP, Milewski K, Wojakowski W, Jackiewicz W, Pajak J, Szurlej D, Fryc-Stanek J, Wiernek S, Jelonek M, Spurlock ME, Martin J, Bochenek A, Buszman PE. Intracoronary adiponectin at reperfusion reduces infarct size in a porcine myocardial infarction model. *Int J Mol Med* 2011; **27**: 775-781 [PMID: 21399860 DOI: 10.3892/ijmm.2011.643]
- 26 **Michael LH**, Entman ML, Hartley CJ, Youker KA, Zhu J, Hall SR, Hawkins HK, Berens K, Ballantyne CM. Myocardial ischemia and reperfusion: a murine model. *Am J Physiol* 1995; **269**: H2147-H2154 [PMID: 8594926]
- 27 **Poulsen RH**, Bøtker HE, Rehling M. Postreperfusion myocardial technetium-99m-sestamibi defect corresponds to area at risk: experimental results from an ischemia-reperfusion porcine model. *Nucl Med Biol* 2011; **38**: 819-825 [PMID: 21843777 DOI: 10.1016/j.nucmedbio.2011.02.008]
- 28 **Heltne JK**, Farstad M, Lund T, Koller ME, Matre K, Rynning SE, Husby P. Determination of plasma volume in anaesthetized piglets using the carbon monoxide (CO) method. *Lab Anim* 2002; **36**: 344-350 [PMID: 12144744 DOI: 10.1258/002367702320162333]
- 29 **Fry DL**. Certain histological and chemical responses of the vascular interface to acutely induced mechanical stress in the aorta of the dog. *Circ Res* 1969; **24**: 93-108 [PMID: 5763742]
- 30 **Ni Y**. Metalloporphyrins and functional analogues as MRI contrast agents. *Curr Med Imaging Rev* 2008; **4**: 96-112 [DOI: 10.2174/157340508784356789]
- 31 **Li J**, Cona MM, Chen F, Feng Y, Zhou L, Yu J, Nuyts J, de Witte P, Zhang J, Himmelreich U, Verbruggen A, Ni Y. Exploring theranostic potentials of radioiodinated hypericin in rodent necrosis models. *Theranostics* 2012; **2**: 1010-1019 [PMID: 23139728 DOI: 10.7150/thno.4924]
- 32 **Wang H**, Miranda Cona M, Chen F, Li J, Yu J, Feng Y, Peeters R, De Keyzer F, Marchal G, Ni Y. Comparison between nonspecific and necrosis-avid gadolinium contrast agents in vascular disrupting agent-induced necrosis of rodent tumors at 3.0T. *Invest Radiol* 2011; **46**: 531-538 [PMID: 21577133 DOI: 10.1097/Rli.0b013e31821a2116]
- 33 **Malik AB**, Kaplan JE, Saba TM. Reference sample method for cardiac output and regional blood flow determinations in the rat. *J Appl Physiol* 1976; **40**: 472-475 [PMID: 931866]
- 34 **Deveci D**, Egginton S. Development of the fluorescent microsphere technique for quantifying regional blood flow in small mammals. *Exp Physiol* 1999; **84**: 615-630 [PMID: 10481220]
- 35 **Chien GL**, Anselone CG, Davis RF, Van Winkle DM. Fluorescent vs. radioactive microsphere measurement of regional myocardial blood flow. *Cardiovasc Res* 1995; **30**: 405-412 [PMID: 7585832 DOI: 0008-6363(95)00060-7]
- 36 **Jugdutt BI**, Hutchins GM, Bulkley BH, Pitt B, Becker LC. Effect of indomethacin on collateral blood flow and infarct size in the conscious dog. *Circulation* 1979; **59**: 734-743 [PMID: 421313]
- 37 **Wang H**, Sun X, Chen F, De Keyzer F, Yu J, Landuyt W, Vandecaveye V, Peeters R, Bosmans H, Hermans R, Marchal G, Ni Y. Treatment of rodent liver tumor with combretastatin a4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology. *Invest Radiol* 2009; **44**: 44-53 [PMID: 19034028 DOI: 10.1097/Rli.0b013e31818e5Ace]
- 38 **Connelly CM**, Leppo JA, Weitzman PW, Vogel WM, Apstein CS. Effect of coronary occlusion and reperfusion on myocardial blood flow during infarct healing. *Am J Physiol* 1989; **257**: H365-H374 [PMID: 2764125]
- 39 **Chu A**, Cobb FR. Reperfusion alters the relation between blood flow and the remaining myocardial infarction. *Circulation* 1989; **79**: 884-889 [PMID: 2924418]
- 40 **Feng Y**, Xie Y, Wang H, Chen F, Marchal G, Ni Y. Animal models of ischemic heart disease for cardiac MR imaging research. *Int J MIC* 2010; **9**: 288-310 [DOI: 10.1504/IJMIC.2010.032809]

P- Reviewer Chang ST S- Editor Song XX L- Editor A
E- Editor Lu YJ



GENERAL INFORMATION

World Journal of Methodology (*World J Methodol*, *WJM*, online ISSN 2222-0682, DOI: 10.5662) is a peer-reviewed open access (OA) academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

Aims and scope

The primary task of *WJM* is to rapidly publish high-quality original articles, reviews, and commentaries that deal with the methodology to develop, validate, modify and promote diagnostic and therapeutic modalities and techniques in preclinical and clinical applications. *WJM* covers topics concerning the subspecialties including but not exclusively anesthesiology, cardiac medicine, clinical genetics, clinical neurology, critical care, dentistry, dermatology, emergency medicine, endocrinology, family medicine, gastroenterology and hepatology, geriatrics and gerontology, hematology, immunology, infectious diseases, internal medicine, obstetrics and gynecology, oncology, ophthalmology, orthopedics, otolaryngology, radiology, serology, pathology, pediatrics, peripheral vascular disease, psychiatry, radiology, rehabilitation, respiratory medicine, rheumatology, surgery, toxicology, transplantation, and urology and nephrology.

WJM is edited and published by Baishideng Publishing Group (BPG). BPG has a strong professional editorial team composed of science editors, language editors and electronic editors. BPG currently publishes 42 OA clinical medical journals, and is one of the leading medical publishers, with the first-class editing and publishing capacity and production.

Columns

The columns in the issues of *WJM* will include: (1) Editorial: The editorial board members are invited to make comments on an important topic in their field in terms of its current research status and future directions to lead the development of this discipline; (2) Frontier: The editorial board members are invited to select a highly cited cutting-edge original paper of his/her own to summarize major findings, the problems that have been resolved and remain to be resolved, and future research directions to help readers understand his/her important academic point of view and future research directions in the field; (3) Diagnostic Advances: The editorial board members are invited to write high-quality diagnostic advances in their field to improve the diagnostic skills of readers. The topic covers general clinical diagnosis, differential diagnosis, pathological diagnosis, laboratory diagnosis, imaging diagnosis, endoscopic diagnosis, biotechnological diagnosis, functional diagnosis, and physical diagnosis; (4) Therapeutics Advances: The editorial board members are invited to write high-quality therapeutic advances in their field to help improve the therapeutic skills of readers. The topic covers medication therapy, psychotherapy, physical therapy, replacement therapy, interventional therapy, minimally invasive therapy, endoscopic therapy, transplantation therapy, and surgical therapy; (5) Field of Vision: The editorial board members are invited to write commentaries on classic articles, hot topic articles, or latest articles to keep readers at the forefront of research and increase their levels of clinical research. Classic articles refer to papers that are included in Web of Knowledge and have received a large number of citations (ranking in the top 1%) after being published for more than years, reflecting the quality and impact of papers. Hot topic articles refer

to papers that are included in Web of Knowledge and have received a large number of citations after being published for no more than 2 years, reflecting cutting-edge trends in scientific research. Latest articles refer to the latest published high-quality papers that are included in PubMed, reflecting the latest research trends. These commentary articles should focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions. Basic information about the article to be commented (including authors, article title, journal name, year, volume, and inclusive page numbers); (6) Minireviews: The editorial board members are invited to write short reviews on recent advances and trends in research of molecular biology, genomics, and related cutting-edge technologies to provide readers with the latest knowledge and help improve their diagnostic and therapeutic skills; (7) Review: To make a systematic review to focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions; (8) Topic Highlight: The editorial board members are invited to write a series of articles (7-10 articles) to comment and discuss a hot topic to help improve the diagnostic and therapeutic skills of readers; (9) Medical Ethics: The editorial board members are invited to write articles about medical ethics to increase readers' knowledge of medical ethics. The topic covers international ethics guidelines, animal studies, clinical trials, organ transplantation, etc.; (10) Clinical Case Conference or Clinicopathological Conference: The editorial board members are invited to contribute high-quality clinical case conference; (11) Original Articles: To report innovative and original findings in basic and clinical medical research methodology; (12) Brief Articles: To briefly report the novel and innovative findings in basic and clinical medical research methodology; (13) Meta-Analysis: Covers the systematic review, mixed treatment comparison, meta-regression, and overview of reviews, in order to summarize a given quantitative effect, e.g., the clinical effectiveness and safety of clinical treatments by combining data from two or more randomized controlled trials, thereby providing more precise and externally valid estimates than those which would stem from each individual dataset if analyzed separately from the others; (14) Case Report: To report a rare or typical case; (15) Letters to the Editor: To discuss and make reply to the contributions published in *WJM*, or to introduce and comment on a controversial issue of general interest; (16) Book Reviews: To introduce and comment on quality monographs of basic and clinical medical research methodology; and (17) Autobiography: The editorial board members are invited to write their autobiography to provide readers with stories of success or failure in their scientific research career. The topic covers their basic personal information and information about when they started doing research work, where and how they did research work, what they have achieved, and their lessons from success or failure.

Name of journal

World Journal of Methodology

ISSN

ISSN 2222-0682 (online)

Launch date

September 26, 2011

Instructions to authors

Frequency

Quarterly

Editor-in-Chief

Yicheng Ni, MD, PhD, Professor, Department of Radiology, University Hospitals, KU, Leuven, Herestraat 49, B-3000, Leuven, Belgium

Editorial Office

Jin-Lei Wang, Director

Xiu-Xia Song, Vice Director

World Journal of Methodology

Room 903, Building D, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China

Telephone: +86-10-59080039

Fax: +86-10-85381893

E-mail: wjg@wjgnet.com

<http://www.wjgnet.com>

Publisher

Baishideng Publishing Group Co., Limited

Flat C, 23/F, Lucky Plaza,

315-321 Lockhart Road, Wan Chai,

Hong Kong, China

Fax: +852-6555-7188

Telephone: ++852-3177-9906

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

Production center

Beijing Baishideng BioMed Scientific Co., Limited

Room 903, Building D, Ocean International Center,

No. 62 Dongsihuan Zhonglu, Chaoyang District,

Beijing 100025, China

Telephone: +86-10-85381892

Fax: +86-10-85381893

Representative office

USA Office

8226 Regency Drive,

Pleasanton, CA 94588-3144, United States

Instructions to authors

Full instructions are available online at http://www.wjgnet.com/2222-0682/g_info_20100722180909.htm

Indexed and abstracted in

Digital Object Identifier.

SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

Biostatistical editing

Statistical review is performed after peer review. We invite an expert in Biomedical Statistics from to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Ridit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, *etc.* The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

Conflict-of-interest statement

In the interests of transparency and to help reviewers assess any potential bias, *WJM* requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: http://www.icmje.org/ethical_4conflicts.html.

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

Statement of informed consent

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

Statement of human and animal rights

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided.

SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of Baishideng Publishing Group Co., Limited, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the ICMJE to refuse to publish papers on clinical trial results if the trial was not recorded in a

publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

Online submissions

Manuscripts should be submitted through the Online Submission System at: <http://www.wjgnet.com/eps/>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS (http://www.wjgnet.com/2222-0682/g_info_20100722180909.htm) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to wjm@wjgnet.com, or by telephone: +86-10-85381891. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

Title page

Title: Title should be less than 12 words.

Running title: A short running title of less than 6 words should be provided.

Authorship: Authorship credit should be in accordance with the standard proposed by ICMJE, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

Institution: Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

Author contributions: The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

Supportive foundations: The complete name and number of supportive foundations should be provided, e.g. Supported by National Natural Science Foundation of China, No. 30224801

Correspondence to: Only one corresponding address should be provided. Author names should be given first, then author title, af-

filiation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. montgomerybissell@ucsf.edu

Telephone and fax: Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g. Telephone: +86-10-85381892 Fax: +86-10-85381893

Peer reviewers: All articles received are subject to peer review. Normally, three experts are invited for each article. Decision on acceptance is made only when at least two experts recommend publication of an article. All peer-reviewers are acknowledged on Express Submission and Peer-review System website.

Abstract

There are unstructured abstracts (no less than 200 words) and structured abstracts. The specific requirements for structured abstracts are as follows:

An informative, structured abstract should accompany each manuscript. Abstracts of original contributions should be structured into the following sections: AIM (no more than 20 words; Only the purpose of the study should be included. Please write the Aim in the form of "To investigate/study/..."), METHODS (no less than 140 words for Original Articles; and no less than 80 words for Brief Articles), RESULTS (no less than 150 words for Original Articles and no less than 120 words for Brief Articles; You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, e.g. 6.92 ± 3.86 vs 3.61 ± 1.67 , $P < 0.001$), and CONCLUSION (no more than 26 words).

Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

Core tip

Please write a summary of less than 100 words to outline the most innovative and important arguments and core contents in your paper to attract readers.

Text

For articles of these sections, original articles and brief articles, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both. The main text format of these sections, editorial, topic highlight, case report, letters to the editors, can be found at: http://www.wjgnet.com/2222-0682/g_info_20100725072755.htm.

Illustrations

Figures should be numbered as 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are applicable. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...*etc.* It is our principle to publish high resolution-figures for the E-versions.

Tables

Three-line tables should be numbered 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each table. Detailed

Instructions to authors

legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

Notes in tables and illustrations

Data that are not statistically significant should not be noted. ^a*P* < 0.05, ^b*P* < 0.01 should be noted (*P* > 0.05 should not be noted). If there are other series of *P* values, ^c*P* < 0.05 and ^d*P* < 0.01 are used. A third series of *P* values can be expressed as ^e*P* < 0.05 and ^f*P* < 0.01. Other notes in tables or under illustrations should be expressed as ¹F, ²F, ³F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, etc., in a certain sequence.

Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

REFERENCES

Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability^[1,2]". If references are cited directly in the text, they should be put together within the text, for example, "From references^[19,22-24], we know that..."

When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

PMID and DOI

Please provide PubMed citation numbers to the reference list, e.g. PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR) Book title. Publication number. Publication place: Publication press, Year: start page and end page.

Format

Journals

English journal article (list all authors and include the PMID where applicable)

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol*

2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

Chinese journal article (list all authors and include the PMID where applicable)

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarhoea. *Shijie Huaren Xiaobua Zazhi* 1999; **7**: 285-287

In press

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

Organization as author

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 PMID:2516377 DOI:10.1161/01.HYP.0000035706.28494.09]

Both personal authors and an organization as author

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

No author given

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

Volume with supplement

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/j.1526-4610.42.s2.7.x]

Issue with no volume

- 8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; (**401**): 230-238 [PMID: 12151900 DOI:10.1097/00003086-200208000-00026]

No volume or issue

- 9 Outreach: Bringing HIV-positive individuals into care. *HRS-A Careaction* 2002; 1-6 [PMID: 12154804]

Books

Personal author(s)

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

Chapter in a book (list all authors)

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

Author(s) and editor(s)

- 12 **Breedlove GK**, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wiczorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

Conference proceedings

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

Conference paper

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

Electronic journal (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. *Emerg Infect Dis* serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

Patent (list all authors)

- 16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

Statistical data

Write as mean \pm SD or mean \pm SE.

Statistical expression

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as χ^2 (in Greek), related coefficient as *r* (in italics), degree of freedom as ν (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

Units

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h; blood glucose concentration, *c* (glucose) 6.4 ± 2.1 mmol/L; blood CEA mass concentration, *p* (CEA) = 8.6 24.5 μ g/L; CO₂ volume fraction, 50 mL/L CO₂, not 5% CO₂; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, etc. Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantum numbers can be found at: http://www.wjgnet.com/2222-0682/g_info_20100725073806.htm.

Abbreviations

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

Italics

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, etc.

Restriction enzymes: *EcoRI*, *HindI*, *BamHI*, *Kho I*, *Kpn I*, etc.

Biology: *H. pylori*, *E. coli*, etc.

Examples for paper writing

All types of articles' writing style and requirement will be found in the link: <http://www.wjgnet.com/esps/NavigationInfo.aspx?id=15>.

SUBMISSION OF THE REVISED MANUSCRIPTS AFTER ACCEPTED

Authors must revise their manuscript carefully according to the re-

vision policies of Baishideng Publishing Group Co., Limited. The revised version, along with the signed copyright transfer agreement, responses to the reviewers, and English language Grade A certificate (for non-native speakers of English), should be submitted to the online system *via* the link contained in the e-mail sent by the editor. If you have any questions about the revision, please send e-mail to esps@wjgnet.com.

Language evaluation

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A.

Copyright assignment form

Please download a Copyright assignment form from http://www.wjgnet.com/2222-0682/g_info_20100725073726.htm.

Responses to reviewers

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: http://www.wjgnet.com/2222-0682/g_info_20100725073445.htm.

Proof of financial support

For papers supported by a foundation, authors should provide a copy of the approval document and serial number of the foundation.

STATEMENT ABOUT ANONYMOUS PUBLICATION OF THE PEER REVIEWERS' COMMENTS

In order to increase the quality of peer review, push authors to carefully revise their manuscripts based on the peer reviewers' comments, and promote academic interactions among peer reviewers, authors and readers, we decide to anonymously publish the reviewers' comments and author's responses at the same time the manuscript is published online.

PUBLICATION FEE

WJM is an international, peer-reviewed, OA online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium and format, provided the original work is properly cited. The use is non-commercial and is otherwise in compliance with the license. Authors of accepted articles must pay a publication fee. Publication fee: 600 USD per article. All invited articles are published free of charge.



百世登

Baishideng®

Published by **Baishideng Publishing Group Co., Limited**

Flat C, 23/F., Lucky Plaza, 315-321 Lockhart Road,

Wan Chai, Hong Kong, China

Fax: +852-65557188

Telephone: +852-31779906

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

